Solve Therapeutics has secured USD 120 million in oversubscribed financing led by Yosemite, with participation from Alexandria Venture Investments and MSD, supporting the clinical advancement of its CloakLink antibody drug conjugate (ADC) platform featuring hydrophilic stable linker technology, addressing hydrophobicity challenges in conventional payload conjugation. The proprietary linker system masks payload hydrophobicity, improving plasma stability and pharmacokinetics while reducing toxicity through a peptide-based release trigger resistant to off-target cleavage. The company has raised a cumulative USD 321 million, including a 2022 Series A.

The CloakLink platform demonstrates compatibility with diverse payloads and drug- antibody ratios (DARs), supporting pipeline expansion across multiple solid tumour indications, with planned Phase Ib trials for lead candidates following current dose escalation studies. The financing will accelerate clinical development and platform optimisation efforts targeting best-in-class profiles in the competitive oncology landscape through improved targeting efficiency and reduced systemic exposure.

According to PharmCube's NextBiopharm® database, Solve's pipeline comprises four ADCs evenly distributed across the pre-clinical and Phase I stages. Click here to request a free trial for NextBiopharm®.